135 related articles for article (PubMed ID: 29369241)
1. Serum Pepsinogen as a Predictor for Gastric Cancer Death: A 16-Year Community-based Cohort Study.
Chiang TH; Chiu SY; Chen SL; Yen AM; Fann JC; Liu CY; Chou CK; Chiu HM; Shun CT; Wu MS; Lin JT; Lee YC; Chen TH; Lin MW
J Clin Gastroenterol; 2019; 53(5):e186-e193. PubMed ID: 29369241
[TBL] [Abstract][Full Text] [Related]
2. Serum pepsinogen levels can quantify the risk of development of metachronous gastric cancer after endoscopic resection.
Iguchi M; Kato J; Yoshida T; Yamamoto Y; Nakachi K; Fukatsu K; Mori Y; Maeda Y; Moribata K; Shingaki N; Niwa T; Deguchi H; Inoue I; Maekita T; Tamai H; Ichinose M
Int J Cancer; 2016 Sep; 139(5):1150-6. PubMed ID: 27083518
[TBL] [Abstract][Full Text] [Related]
3. Cancer development based on chronic active gastritis and resulting gastric atrophy as assessed by serum levels of pepsinogen and Helicobacter pylori antibody titer.
Yoshida T; Kato J; Inoue I; Yoshimura N; Deguchi H; Mukoubayashi C; Oka M; Watanabe M; Enomoto S; Niwa T; Maekita T; Iguchi M; Tamai H; Utsunomiya H; Yamamichi N; Fujishiro M; Iwane M; Takeshita T; Ushijima T; Ichinose M
Int J Cancer; 2014 Mar; 134(6):1445-57. PubMed ID: 24009139
[TBL] [Abstract][Full Text] [Related]
4. Risk of gastric cancer in asymptomatic, middle-aged Japanese subjects based on serum pepsinogen and Helicobacter pylori antibody levels.
Yanaoka K; Oka M; Yoshimura N; Mukoubayashi C; Enomoto S; Iguchi M; Magari H; Utsunomiya H; Tamai H; Arii K; Yamamichi N; Fujishiro M; Takeshita T; Mohara O; Ichinose M
Int J Cancer; 2008 Aug; 123(4):917-26. PubMed ID: 18508314
[TBL] [Abstract][Full Text] [Related]
5. The combination of serum trefoil factor 3 and pepsinogen testing is a valid non-endoscopic biomarker for predicting the presence of gastric cancer: a new marker for gastric cancer risk.
Kaise M; Miwa J; Tashiro J; Ohmoto Y; Morimoto S; Kato M; Urashima M; Ikegami M; Tajiri H
J Gastroenterol; 2011 Jun; 46(6):736-45. PubMed ID: 21455714
[TBL] [Abstract][Full Text] [Related]
6. Serum pepsinogen levels and their influencing factors: a population-based study in 6990 Chinese from North China.
Sun LP; Gong YH; Wang L; Yuan Y
World J Gastroenterol; 2007 Dec; 13(48):6562-7. PubMed ID: 18161928
[TBL] [Abstract][Full Text] [Related]
7. Serum pepsinogen 1 and anti-Helicobacter pylori IgG antibodies as predictors of gastric cancer risk in Finnish males.
Song M; Camargo MC; Weinstein SJ; Murphy G; Freedman ND; Koshiol J; Stolzenberg-Solomon RZ; Abnet CC; Männistö S; Albanes D; Rabkin CS
Aliment Pharmacol Ther; 2018 Feb; 47(4):494-503. PubMed ID: 29243850
[TBL] [Abstract][Full Text] [Related]
8. Helicobacter pylori infection and serum level of pepsinogen are associated with the risk of metachronous gastric neoplasm after endoscopic resection.
Kwon Y; Jeon S; Nam S; Shin I
Aliment Pharmacol Ther; 2017 Oct; 46(8):758-767. PubMed ID: 28799258
[TBL] [Abstract][Full Text] [Related]
9. Predictive power of serum pepsinogen tests for the development of gastric cancer in comparison to the histologic risk index.
Kwak MS; Kim N; Lee HS; Lee HE; Jung HC; Song IS
Dig Dis Sci; 2010 Aug; 55(8):2275-82. PubMed ID: 20306133
[TBL] [Abstract][Full Text] [Related]
10. The correlation between histological gastritis staging- 'OLGA/OLGIM' and serum pepsinogen test in assessment of gastric atrophy/intestinal metaplasia in China.
Wang X; Lu B; Meng L; Fan Y; Zhang S; Li M
Scand J Gastroenterol; 2017 Aug; 52(8):822-827. PubMed ID: 28436254
[TBL] [Abstract][Full Text] [Related]
11. Western long-term accuracy of serum pepsinogen-based gastric cancer screening.
Castro C; Dinis-Ribeiro M; Rodrigues ANG; Calheiros T; Santos J; Pereira P; Ramos M; Cunha H; Andrade M; Costa A; Sá L; Antunes L; Bento MJ; Lomba-Viana R
Eur J Gastroenterol Hepatol; 2018 Mar; 30(3):274-277. PubMed ID: 29215432
[TBL] [Abstract][Full Text] [Related]
12. Helicobacter pylori IgA and IgG antibodies, serum pepsinogen I and the risk of gastric cancer: changes in the risk with extended follow-up period.
Knekt P; Teppo L; Aromaa A; Rissanen H; Kosunen TU
Int J Cancer; 2006 Aug; 119(3):702-5. PubMed ID: 16496404
[TBL] [Abstract][Full Text] [Related]
13. Serum Pepsinogen as a Biomarker for Gastric Cancer in the United States: A Nested Case-Control Study Using the PLCO Cancer Screening Trial Data.
In H; Sarkar S; Ward J; Friedmann P; Parides M; Yang J; Epplein M
Cancer Epidemiol Biomarkers Prev; 2022 Jul; 31(7):1426-1432. PubMed ID: 35534235
[TBL] [Abstract][Full Text] [Related]
14. The serum pepsinogen levels for risk assessment of gastric neoplasms: New proposal from a case-control study in Korea.
Cho JH; Jeon SR; Kim HG; Jin SY; Park S
Medicine (Baltimore); 2017 Jul; 96(29):e7603. PubMed ID: 28723806
[TBL] [Abstract][Full Text] [Related]
15. Serum pepsinogen levels in gastric cancer patients and their relationship with Helicobacter pylori infection: a prospective study.
So JB; Yeoh KG; Moochala S; Chachlani N; Ho J; Wong WK; Mack P; Goh PM
Gastric Cancer; 2002; 5(4):228-32. PubMed ID: 12491081
[TBL] [Abstract][Full Text] [Related]
16. Combination of Helicobacter pylori Antibody and Serum Pepsinogen as a Good Predictive Tool of Gastric Cancer Incidence: 20-Year Prospective Data From the Hisayama Study.
Ikeda F; Shikata K; Hata J; Fukuhara M; Hirakawa Y; Ohara T; Mukai N; Nagata M; Yoshida D; Yonemoto K; Esaki M; Kitazono T; Kiyohara Y; Ninomiya T
J Epidemiol; 2016 Dec; 26(12):629-636. PubMed ID: 27265836
[TBL] [Abstract][Full Text] [Related]
17. Serum pepsinogen test for early detection of gastric cancer in a European country.
Lomba-Viana R; Dinis-Ribeiro M; Fonseca F; Vieira AS; Bento MJ; Lomba-Viana H
Eur J Gastroenterol Hepatol; 2012 Jan; 24(1):37-41. PubMed ID: 21989121
[TBL] [Abstract][Full Text] [Related]
18. Gastric adenocarcinoma screening and prevention in the era of new biomarker and endoscopic technologies: a cost-effectiveness analysis.
Yeh JM; Hur C; Ward Z; Schrag D; Goldie SJ
Gut; 2016 Apr; 65(4):563-74. PubMed ID: 25779597
[TBL] [Abstract][Full Text] [Related]
19. Eradication of Helicobacter pylori prevents cancer development in subjects with mild gastric atrophy identified by serum pepsinogen levels.
Yanaoka K; Oka M; Ohata H; Yoshimura N; Deguchi H; Mukoubayashi C; Enomoto S; Inoue I; Iguchi M; Maekita T; Ueda K; Utsunomiya H; Tamai H; Fujishiro M; Iwane M; Takeshita T; Mohara O; Ichinose M
Int J Cancer; 2009 Dec; 125(11):2697-703. PubMed ID: 19610064
[TBL] [Abstract][Full Text] [Related]
20. Long-term results of gastric cancer screening using the serum pepsinogen test method among an asymptomatic middle-aged Japanese population.
Miki K; Fujishiro M; Kodashima S; Yahagi N
Dig Endosc; 2009 Apr; 21(2):78-81. PubMed ID: 19691778
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
